Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Rh(D) IgG opsonized autologous red blood cells
- Development stage
- Unknown
- Lead developer
- Centro de Hematología y Medicina Interna de Puebla
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-Rh(D) IgG opsonized autologous red blood cells is an autologous cell therapy used for the treatment of chronic, refractory autoimmune thrombocytopenic purpura (ITP). The therapeutic process involves collecting a patient's own red blood cells (RBCs) and opsonizing them ex vivo with anti-Rh(D) immunoglobulin G (IgG). Upon re-infusion, these opsonized RBCs are cleared by the spleen, which effectively saturates and blocks the Fc gamma receptors (FcγR) on splenic macrophages. This competitive inhibition prevents the macrophages from destroying antibody-coated platelets, thereby increasing the platelet count in patients with ITP. This approach is considered a cost-effective alternative to intravenous immunoglobulin (IVIG) or systemic anti-D immunoglobulin therapy.
- Other names
- ex vivo anti-D opsonized autologous red blood cellsanti-D opsonized autologous red blood cellsanti-D opsonized RBCs
02
Targets
FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B)RhD (Rh blood group D antigen)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)FCGR2B (Fc gamma receptor IIB)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)
Beyond the preview
Go deeper on anti-Rh(D) IgG opsonized autologous red blood cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Rh(D) IgG opsonized autologous red blood cells.